Cargando…
Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial
BACKGROUND: This study examined the effects of peretinoin, an acyclic retinoid, on the survival of patients with hepatitis C virus-related hepatocellular carcinoma (HCC) who had completed curative therapy and participated in a randomized, placebo-controlled trial. METHODS: This study was an investig...
Autores principales: | Okita, Kiwamu, Izumi, Namiki, Ikeda, Kenji, Osaki, Yukio, Numata, Kazushi, Ikeda, Masafumi, Kokudo, Norihiro, Imanaka, Kazuho, Nishiguchi, Shuhei, Kondo, Shunsuke, Nishigaki, Yoichi, Shiomi, Susumu, Ueshima, Kazuomi, Isoda, Norio, Karino, Yoshiyasu, Kudo, Masatoshi, Tanaka, Katsuaki, Kaneko, Shuichi, Moriwaki, Hisataka, Makuuchi, Masatoshi, Okusaka, Takuji, Hayashi, Norio, Ohashi, Yasuo, Kumada, Hiromitsu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460291/ https://www.ncbi.nlm.nih.gov/pubmed/25209978 http://dx.doi.org/10.1007/s00535-014-0996-1 |
Ejemplares similares
-
Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study
por: Okita, Kiwamu, et al.
Publicado: (2014) -
Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
por: Ikeda, Kenji, et al.
Publicado: (2016) -
Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON
por: Kudo, Masatoshi, et al.
Publicado: (2016) -
REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset
por: Yamashita, Tatsuya, et al.
Publicado: (2019) -
Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial
por: Ikeda, Masafumi, et al.
Publicado: (2017)